brand logo

Am Fam Physician. 2006;74(12):2093-2094

Pregabalin (Lyrica) is indicated for the management of pain associated with diabetic neuropathy and postherpetic neuralgia. It also is indicated as adjunctive therapy in adults with partial onset seizures.1 Although the mechanism of action is not fully known, pregabalin seems to decrease the presynaptic release of neurotransmitters (e.g., substance P, glutamate) that are involved with pain sensation and transmission. It does not affect the underlying neuropathy or slow the progression.2

NameStarting dosageDose formApproximate monthly cost*
Pregabalin (Lyrica)50 mg three times daily25-mg, 50-mg, 75-mg, 100-mg, 150-mg, 200-mg, 225-mg, and 300-mg capsules$180 for 50-mg and 100-mg capsules


Results from clinical trials with pregabalin have not identified serious safety issues, although euphoria and signs of physical dependence may occur. One in 25 patients reported euphoria.1 Abrupt discontinuation of pregabalin may lead to insomnia, headache, nausea, and diarrhea, and patients therefore should be gradually tapered off over a minimum of one week.1 Pregabalin is a schedule V controlled substance. Studies assessing long-term safety have not been conducted. Pregabalin is eliminated primarily by renal excretion and requires dose adjustment in patients with renal impairment.1 It is U.S. Food and Drug Administration pregnancy category C.


Approximately one in 11 patients (9 percent) will discontinue use of pregabalin because of side effects. Dizziness and somnolence are the most common side effects causing discontinuation. If dizziness or somnolence occur, the symptoms will begin shortly after initiation of treatment and in patients receiving higher doses. Dizziness occurs in almost one in three patients (29 percent), and somnolence occurs in about one in five patients (22 percent); however, only one in 25 patients (4 percent) will discontinue treatment because of these.1 In patients receiving pregabalin, dry mouth, edema, weight gain, blurred vision, and difficulty concentrating occur at twice the rate seen in those receiving placebo.1


The manufacturer of pregabalin conducted four studies comparing pregabalin with placebo in patients with painful diabetic neuropathy.25 Three of these studies were conducted in patients with diabetic peripheral neuropathy and one study was conducted in patients with either diabetic peripheral neuropathy or postherpetic neuralgia.25 Pregabalin 300 mg per day decreased mean pain scores by 2.5 points from an average of 6.5 points on a visual analog pain rating scale (ranging from 0 to 10).4 In contrast, the scores among patients receiving placebo decreased only by an average of 0.8 points. A change of 2 or more points in pain intensity is considered to be clinically noticeable by patients with diabetic neuropathy.6

A 300-mg daily dosage of pregabalin appeared to be optimal for most patients. A dosage of 150 mg per day was, on average, no more effective than placebo,2,5 and a dosage of 600 mg per day provided no greater relief than a dosage of 300 mg per day.1 In clinical trials, three-times-daily dosing resulted in a noticeable pain reduction as early as one week after initiation of pregabalin.2,4 Twice-daily dosing demonstrated a slower onset of pain reduction (i.e., two weeks).3

No studies have compared pregabalin with tricyclic antidepressants, gabapentin (Neurontin), or duloxetine (Cymbalta) for the management of painful diabetic peripheral neuropathy. The long-term effectiveness of pregabalin in the treatment of diabetic neuropathy has not been established; the longest clinical trial was only 12 weeks in duration.3


Both the initial dosage of pregabalin (50 mg three times daily) and the typically effective dosage (100 mg three times daily) will cost the patient approximately $180 per month. This cost is higher than some other options for treatment, including Cymbalta ($109) and generic amitriptyline ($1 to $19), but it is lower than the cost of Neurontin ($269) and generic gabapentin ($195 to $282).


The recommended initial dosage for pregabalin in the management of neuropathic pain associated with diabetic peripheral neuropathy is 50 mg three times daily (150 mg per day); this may be increased to 100 mg three times daily (300 mg per day) after one week based on patient response.1 Patients with renal dysfunction should be dosed following guidelines in the product labeling.1 Pregabalin can be taken with or without food.

Bottom Line

Pregabalin is safe and effective for the management of neuropathic pain associated with diabetic peripheral neuropathy. Drawbacks include the cost and the lack of studies demonstrating equivalence or superiority to other treatments. However, pregabalin’s ease of dosing titration, minimal drug interactions, and favorable side effect profile make it appealing for those who cannot tolerate less-expensive alternatives. Until research establishes a relative benefit of pregabalin, it is better suited as a second-line therapy or as an alternative treatment option if less-expensive medications fail.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at

Continue Reading

More in AFP

Copyright © 2006 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.